• Home
  • News
    • Editorial
    • MD(e)B(unker)
    • Related Researches
      • Di Bella's Foundation
      • 1960-1969
      • 1970-1979
      • 1980-1989
      • 1990-1999
      • 2000-2009
      • 2010-2019
      • 2020-2029
    • Science news
    • Scientific Documentation
  • About us...
    • Biography
    • Bibliography
  • The Method
    • Di Bella's Method!
    • 1998 Trial!
  • Media
    • Video Publications
    • News-PapersNews-Papers
      • Press
    • TestimonialTestimonial
      • Testimonies
    • Video GalleryVideo Gallery
      • Congresses
      • Video Testimonies
      • TV & C.
  • Case History
    • Medical reports
      • Lung
      • Lymphomas
        • Non-Hodgkin Lymphomas
        • Hodgkin Lymphomas
      • Mediastinum
      • Mesothelioma
      • Myeloma
      • Pancreas
      • Scientific Publications
  • F.A.Q.
  • Useful Links
    • User Side
      • Vademecum
    • CouponChief - Resources for Cancer Patients
  • Contact Us
Home page   News   Related Researches   2010-2019  
Title Created Date
Synergy in ERK activation by cytokine receptors and tyrosine kinase growth factor receptors 02 March 2014
Overexpression of P53 protein and local hGH, IGF-I, IGFBP-3, IGFBP-2 and PRL secretion by human breast cancer explants 02 March 2014
Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor 25 February 2014
Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland 25 February 2014
Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells 20 February 2014
New concepts in prolactin biology 20 February 2014
Somatostatin in breast cancer 19 February 2014
Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells 19 February 2014
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124] 19 February 2014
Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma 12 February 2014
Display # 

Page 164 of 172

  • Start
  • Prev
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • Next
  • End

Search

Follow us...

Latest

  • Melatonin induces apoptosis through a caspase-dependent but reactive oxygen species-independent mechanism in human leukemia Molt-3 cells
  • Melatonin is an appropriate candidate for breast cancer treatment: Based on known molecular mechanisms
  • Key aspects of melatonin physiology: Thirty years of research
  • Somatostatin in oncology, the overlooked evidences
  • Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy (Review)
  • Key aspects of melatonin physiology: 30 years of research
  • Melatonin anticancer effects: Review
  • Osteogenesis from Dental Pulp Derived Stem Cells: A Novel Conditioned Medium Including Melatonin within a Mixture of Hyaluronic, Butyric, and Retinoic Acids
  • Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers
  • Mechanisms of antineoplastic action of somatostatin analogs
  • Evaluation of radio-protective effect of melatonin on whole body irradiation induced liver tissue damage
  • Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives
  • Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes
  • Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes
  • Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression
  • Growth Hormone's Links to Cancer
  • The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity
  • The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature

Most Read

  • The Di Bella Method (DBM)
  • About melatonin - 1996
  • All-trans-retinoic acid and cancer
  • Biography
  • Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
  • The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
  • Somatostatin in oncology, the overlooked evidences
  • Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
  • How effective is chemo therapy?
  • Complete objective response to biological therapy of plurifocal breast carcinoma
  • Bibliography
  • Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
  • Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
  • Vademecum
  • Frequently Asked Questions
  • Declaration recommends eliminate the use of Impact factor for research evaluation
  • Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
  • Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer